Center-Authored Papers

Filters: Author is Rosenblatt, Joseph D  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
D
Gopal AK, Chen R, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Chi X et al..  2015.  Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.. Blood. 125(8):1236-43. Abstract
F
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D et al..  2016.  Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.. Blood. Abstract
R
Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Ramchandren R, Bartlett NL, Cheson BD, de Vos S et al..  2012.  Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(18):2183-2189. Abstract
Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD et al..  2014.  Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.. Journal of hematology & oncology. 7(1):24. Abstract